Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck: early-phase trial registry
1 of 3 indexed Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck: 3 US clinical trials tracked, 1 recruiting.
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is University of Michigan Rogel Cancer Center, running 1 of these trials.
Enrollment posture brief
Registry condition recurrent-cutaneous-squamous-cell-carcinoma-of-the-head-and-neck
OPEN 1 | RECR 33% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma
University of Michigan Rogel Cancer Center
NCT06580054
Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery
M.D. Anderson Cancer Center
NCT03565783
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
NCT04576091
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Michigan Rogel Cancer Center sponsors the most Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck trials on record, review their full trial history before evaluating a specific study. See University of Michigan Rogel Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck condition card totals 3 registered trials; most-linked intervention Computed Tomography; top US site state Michigan. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.